No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
IMAB I-Mab
- 1.770
- -0.050-2.75%
Close Jun 18 16:00 ET
- 1.770
- 0.0000.00%
Post 16:08 ET
143.16MMarket Cap-728P/E (TTM)
1.810High1.760Low150.20KVolume1.800Open1.820Pre Close266.72KTurnover0.28%Turnover RatioLossP/E (Static)80.88MShares3.19552wk High0.60P/B94.71MFloat Cap1.16052wk Low--Dividend TTM53.51MShs Float85.400Historical High--Div YieldTTM2.75%Amplitude1.160Historical Low1.775Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Market Chatter: ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial
South Korean biotechnology firm ABL Bio Inc. (KOSDAQ:298380) and its US-based partner I-MAB Biopharma entered a collaboration and supply agreement with New York-based pharmaceutical company Bristol-My
While Private Equity Firms Own 21% of I-Mab (NASDAQ:IMAB), Retail Investors Are Its Largest Shareholders With 59% Ownership
I-mab has appointed Dr. Phillip Dennis as its Chief Medical Officer.
On June 6th, Gelonghui announced that i-Mab appointed Dr. Phillip Dennis as Chief Medical Officer. Dr. Phillip Dennis will join i-Mab on June 17, 2024, leading global clinical development and serving as a member of i-Mab's executive leadership team. "I am delighted to welcome Dr. Phillip Dennis as our Chief Medical Officer. Dr. Phillip Dennis has extensive experience in oncology drug development.
Express News | I-Mab Appoints Phillip Dennis, Md, Phd, as Chief Medical Officer
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
ROCKVILLE, Md., June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of high
Bristol Myers Squibb Inks Clinical Trial Pact With I-Mab
Comments
Gapping up
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%, ...
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%, ...
10
this one is going on the watch list
$I-Mab(IMAB.US$
this pharmaceutical company has tons of potential big money makers in the pipeline. if just one of these Cancer drugs gets approved then it will be a lot of money to be made for this very cheap ticker. they're also anticipating being listed in mainland China and in Hong Kong. this could be a bullish catalyst in the future even without any of the drugs being approv...
$I-Mab(IMAB.US$
this pharmaceutical company has tons of potential big money makers in the pipeline. if just one of these Cancer drugs gets approved then it will be a lot of money to be made for this very cheap ticker. they're also anticipating being listed in mainland China and in Hong Kong. this could be a bullish catalyst in the future even without any of the drugs being approv...
+1
2
Gainers:
• $GTY Technology(GTYH.US$ +118.1% (entered into a definitive agreement to be acquired by GI Partners )
• $Finch Therapeutics(FNCH.US$ +68.33% (announces removal of FDA clinical hold on CP101 IND)
• $Zymeworks(ZYME.US$ +42.34% (confirms receipt of non-binding proposal from All Blue Falcons for $10.50 per share in cash)
• $Hub Group(HUBG.US$ +16.3% (earnings reports)
• $Lantheus(LNTH.US$ +14.2% (earnings reports)
• $Mohawk Industries(MHK.US$ +13.7% (e...
• $GTY Technology(GTYH.US$ +118.1% (entered into a definitive agreement to be acquired by GI Partners )
• $Finch Therapeutics(FNCH.US$ +68.33% (announces removal of FDA clinical hold on CP101 IND)
• $Zymeworks(ZYME.US$ +42.34% (confirms receipt of non-binding proposal from All Blue Falcons for $10.50 per share in cash)
• $Hub Group(HUBG.US$ +16.3% (earnings reports)
• $Lantheus(LNTH.US$ +14.2% (earnings reports)
• $Mohawk Industries(MHK.US$ +13.7% (e...
18
Gainers:
• $AlloVir(ALVR.US$ +23.11% (announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to its lead investigational multi-virus-specific T cell therapy posoleucel)
• $I-Mab(IMAB.US$ +13% (report that the company is considering sale)
• $ASML Holding(ASML.US$ +5.2% (earnings report)
• $Humanigen(HGEN.US$ +4.4% (Announces Peer-Reviewed Publication Demonstrating the P...
• $AlloVir(ALVR.US$ +23.11% (announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to its lead investigational multi-virus-specific T cell therapy posoleucel)
• $I-Mab(IMAB.US$ +13% (report that the company is considering sale)
• $ASML Holding(ASML.US$ +5.2% (earnings report)
• $Humanigen(HGEN.US$ +4.4% (Announces Peer-Reviewed Publication Demonstrating the P...
19
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg